Generics 1

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Abiraterone manufacturers

1 products found

Filters

Filters

Filters , active

Country of origin : China

Clear all

1 products found

abiraterone

Tablets 150 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Manufacturer #17216
This global pharmaceutical company, established in 1970, prioritizes research and development of innovative healthcare products. With a focus on oncology, metabolic diseases, autoimmune diseases, and cardiovascular diseases, they have developed 14 in-house innovative products and partnered with other companies to bring 2 more to market. They boast over 5,000 R&D personnel across fourteen global centers and subsidiaries in North America, the EU, Australia, and Japan. Their commitment to innovation is evidenced by over 90 innovative drug candidates in development and nearly 20 undergoing clinical trials worldwide. The company holds numerous patents granted in key regions like the US, EU, and Japan, demonstrating their strong intellectual property portfolio. They manufacture products that meet or exceed European Union and US Pharmacopoeia standards, exporting to markets including the US, EU, and Japan.

Manufacturer usually replies in 19 days

Want to see all 1 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Abiraterone acetate Manufacturers

Abiraterone acetate is a medication used to treat prostate cancer. It is sold under the brand name Zytiga. More specifically it is used together with a corticosteroid for castration-resistant prostate cancer or mCRPC and metastatic high-risk metastatic castration-sensitive prostate cancer or mCSPC. It should be used in cases following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is an oral medication. Common side effects are such as tiredness, vomiting, headache, joint pain, high blood pressure, swelling, low blood potassium, high blood sugar, hot flashes, diarrhea, and cough. Other severe side effects may include adrenocortical insufficiency and liver failure. Birth control is recommended in males whose partners can become pregnant. Supplied as abiraterone acetate it is converted in the body to abiraterone. Abiraterone acetate suppresses the production of androgens, specifically, it inhibits CYP17A1 and decreases the production of testosterone. Thus it prevents the effects of these hormones in prostate cancer. Abiraterone acetate was demonstrated in 1995 and gained approval for medical use in the United States and Europe in 2011. The World Health Organization listed in Essential Medicines, as the safest and most effective medicines needed in a health system. This medication is marketed widely throughout the world. Abiraterone acetate is used in combination with prednisone a corticosteroid, as a treatment for mCRPC (previously known as hormone-resistant or hormone-refractory prostate cancer). This is a kind of prostate cancer that does not respond to first-line androgen deprivation therapy or treatment with androgen receptor antagonists. Abiraterone acetate has received approval from: Food and Drug Administration (FDA) (28 April 2011), European Medicines Agency (EMA) (23 September 2011), Medicines and Healthcare products Regulatory Agency (MHRA) (5 September 2011) And Therapeutic Goods Administration (TGA) (1 March 2012) for this indication. it is covered by the Pharmaceutical Benefits Scheme In Australia, specifically when it is used to treat castration-resistant prostate cancer in combination with prednisone/prednisolone. The patient who is not currently receiving chemotherapy has been found either resistant or intolerant of docetaxel. The patient has a WHO performance status of <2. Besides his disease has not become progressive since treatment with PBS-subsidised abiraterone acetate has commenced. Contraindications include hypersensitivity to abiraterone acetate. Although documents state that it should not be taken by women. Specifically, who are pregnant or may become pregnant. There is no medical reason for any woman to take it. Pregnant women should not even touch the pills unless they are wearing gloves. Other cautions include: severe baseline hepatic impairment, mineralocorticoid excess, cardiovascular disease like heart failure and hypertension, uncorrected hypokalemia,

How Does Abiraterone acetate Work?

Abiraterone works by stopping the body’s production of a hormone called testosterone. It is usually done in a different way to other types of hormone therapy. Prostate cancer cells can't grow without testosterone, in most men. Even if they have spread to other parts of the body, they can't grow without it.

The Wholesale Price of Abiraterone acetate

The wholesale price of this pharmaceutical substance is around $50-65 USD per medicine. The price may vary and depends on the pharmacy you visit.

Sourcing Abiraterone Manufacturers and Abiraterone acetate Suppliers

Those who are looking for an easy and convenient way to source and order abiraterone may search online using Pipelinepharma's marketplace. Through our strict evaluation and quality control process, you are assured to find verified abiraterone manufacturers and suppliers.

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible